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Background: The best clinical practice to investigate aerobic fitness includes measurements obtained during
cardiopulmonary exercise testing (CPET), however it remains an underutilised clinical measure in cystic fibrosis (CF).
To investigate this further, different methods of quantifying exercise capacity in CF are required. The possibility that
measuring physical activity (PA) by a portable accelerometer could be used to assess the CF aerobic state and
could be added among the CPET surrogates has not been investigated. The aim of this study was to examine
the relationship between PA and exercise fitness both at submaximal and maximal levels in clinically stable adults
with CF.
Methods: Thirty CF patients (FEV1 71 ± 19% predicted) and fifteen healthy controls undertook an incremental CPET
on a cycle ergometer. CPET-related measurements included: oxygen uptake (V’O2), carbon dioxide production
(V’CO2), ventilatory profile, heart rate (HR) and oxygen pulse (V’O2/HR) throughout exercise and at lactic threshold
(LT) and peak. LT measures represent submaximal exercise related data. PA was assessed using the accelerometer
SenseWear Pro3 Armband.
Results: Moderate (>4.8 metabolic equivalents (METS)) and moderate + vigorous (>7.2 METS) PA was related to
V’O2 (p = 0.005 and p = 0.009, respectively) and work rate (p = 0.004 and p = 0.002, respectively) at LT. Moderate
PA or greater was positively related to peak V’O2 (p = 0.005 and p = 0.003, respectively). Daily PA levels were similar
in CF and healthy controls. Except for peak values, V’O2 profile and the V’O2 at LT were comparable between CF
and healthy controls.
Conclusions: In adult CF patients daily PA positively correlated with aerobic capacity. PA measurements are a valuable
tool in the assessment of exercise performance in an adult CF population and could be used for interventional exercise
trials to optimize exercise performance and health status. PA levels and parameters obtained at submaximal exercise
are similar in CF and in healthy controls.
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In cystic fibrosis (CF) peak oxygen uptake (V’O2,peak),
maximal work rate (Work max) and ventilatory equiva-
lents for oxygen uptake (V’E/V’O2) measured during in-
cremental cardiopulmonary exercise testing (CPET) are
significant predictors of mortality [1,2]. Recently, data
obtained in children with CF suggest that aerobic fitness
is also associated with lower risk of hospitalization [3].* Correspondence: danielasavi1@virgilio.it
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unless otherwise stated.Although peak exercise tolerance is reduced in CF [4],
some studies have shown that aerobic exercise capacity
increases with physical training programs [4-6].
The best clinical practice to investigate aerobic fitness
includes measurements obtained during CPET, however
there are still many difficulties associated with its use in
clinical practice [7]. In particular, maximal exercise tests
require the subject to make maximal efforts, rendering
such tests highly dependent on motivation. Submaximal
exercise related data (also known as lactate threshold-LT
measures) is an alternative index of aerobic fitness, in-
formation that is directly relevant to a patient’s ability tois is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the clinical environment in patients who may not be able
or willing to provide a maximal effort, especially when
maximal exercise tolerance is limited by ventilatory
factors [7]. Despite some studies highlighting the use of
exercise testing in CF [8,9] and CF guidelines recommen-
ding an annual assessment [10], CPET remains underuti-
lised [11]. This is due in part to its expense and the lack of
adequately trained staff [11] as well as patient’s dislike of
the test itself [9]. So, to investigate this further, different
methods of quantifying exercise capacity in CF are re-
quired. Modalities that are not excessively stressful to pa-
tients are particularly favorable. Field tests, such as shuttle
tests, timed walking and step tests are reasonable surro-
gates for incremental CPET [11,12] and they have the
added value of being more reflective of usual physical ac-
tivity patterns [13]. It has not been investigated in adults
with CF whether objective measurements of physical ac-
tivity (PA) could be added among the CPET surrogates.
Physiological responses to submaximal CPET reflect
daily PA at different intensities in a healthy population
[14], however no information is currently available in
clinically stable adults with CF. To date, the relationship
between formal CPET parameters at submaximal work-
loads and daily activity levels in CF has not been well
established. Thus, the possibility that measuring habitual
PA by a portable accelerometer could be used to assess
the CF aerobic state is worthy of further investigation.
As survival in CF continues to improve a better under-
standing of the relationship between lifestyle in adult-
hood and habitual daily PA is important. Few studies
have compared daily PA in adult CF patients and healthy
subjects. The CF population examined by Troosters et al.
[15] spent less time in moderately intense PA compared
with healthy controls. Conversely, our recent study dem-
onstrated that the time spent in daily PA at different in-
tensities was similar in adults with CF and age-matched
healthy controls [16]. Similarly, Rasekaba et al. showed
that moderate or vigorous habitual PA measured using a
validated questionnaire was similar between CF adults
and controls [17]. So, it remains unclear whether CF
adults have different habitual activities compared with
healthy peers and in order to clarify the discrepancies in
the current literature further studies are needed. More-
over, despite our knowledge about the beneficial effects
of a supervised exercise intervention on submaximal and
maximal oxygen uptake in CF [18,19], there have been
no studies examining the relationship between habitual
daily PA and submaximal fitness in CF.
Therefore the purpose of this study was twofold. First,
we aimed to examine the relationship between daily PA
and aerobic fitness both at submaximal and maximal
levels in clinically stable adults with CF. Specifically, we
were interested in evaluating PA as a surrogate of CPETin the assessment of exercise capacity in CF. In addition
to this primary aim, we wished to compare both daily
PA levels and responses to CPET of adult CF patients
and healthy controls. In analyzing the possible positive
effect of habitual PA in CF, we sought to evaluate the pa-
rameters obtained at submaximal level of exercise in CF
and in healthy control peers.
Methods
Subjects
Thirty adult CF patients (33 ± 8SD years) with mild to
moderate lung disease (FEV1 50%-90% predicted) were
recruited consecutively from the CF outpatient clinic at
Policlinico Umberto I Hospital (Sapienza University of
Rome, Italy). Patients were excluded if they had unstable
medical conditions that could cause or contribute to
breathlessness (i.e. cardiovascular, metabolic, or other re-
spiratory diseases) or other disorders that could interfere
with exercise testing, such as neuromuscular diseases or
musculoskeletal problems. Patients were excluded if they
had had a pulmonary exacerbation within four weeks of
the study period, were on the waiting list for lung trans-
plantation or had undergone lung transplantation.
Fifteen healthy control subjects matched for age were
recruited from staff and colleagues of the same hospital
by invitation. To be eligible for inclusion, the healthy
control subjects needed to have normal baseline spiro-
metry (FEV1 ≥ 80%predicted, FEV1/FVC ≥0.7) and free
of any health problems, including cardiovascular, neuro-
muscular, musculoskeletal, or respiratory diseases.
Study design
This was a prospective case–control study. All subjects
provided written informed consent. The study was ap-
proved by the ethics committee of Policlinico Umberto I
Hospital, Sapienza University of Rome, Italy. After con-
sent and appropriate screening of medical history, all
subjects underwent pulmonary function testing and per-
formed a symptom-limited incremental CPET. Finally,
patients and controls wore an accelerometer (SenseWear
Pro3 Armband) to assess daily habitual PA over five con-
secutive days of their normal activities. Subjects with CF
were asked to continue any respiratory-related medica-
tions before the visits. All subjects were required to eat a
normal mixed diet before laboratory visits to provide
valid experimental/metabolic results during the exercise.
Subjects were also asked to avoid the ingestion of alco-
hol, caffeine-containing products, and heavy meals for at
least 4 hours, and to refrain from strenuous activity (e.g.,
cycling, running) for at least 12 hours before testing. As-
sessment was conducted at the same place and time of
day for all subjects.
The calculation for sample size was done using a pre-
vious study by Troosters et al. [15] who showed a
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dard deviation of 13.62. We proposed that our effect size
could be about half of that obtained by Troosters et al.
[15], therefore for 80% power and 5% significance and
similar variability it would require a total of 36 subjects
in a ratio of 2:1. We therefore recruited 45 in total in a
ratio of 2:1.
Procedures
Spirometry, nitrogen washout and single-breath diffusing
capacity (DLCO) were performed by standardised tech-
niques using an automated pulmonary function testing
system (COSMED PFT, Pavona Italy) [20-22]. All pul-
monary function data were standardized as percentages
of predicted normal values [23,24].
A maximal incremental exercise test was conducted
on an electronically-braked cycle ergometer (COSMED,
Pavona Italy) using the Quark b2 system (COSMED,
Pavona Italy) according to guidelines [25]. CPET con-
sisted of a steady-state resting period, then 2-minutes of
warm-up at 10 watt followed by a stepwise protocol in
which the work rate was increased in 1-minute intervals
by increments of 20 Watt. The test was continued until
the point of symptom limitation (peak exercise). Subjects
were asked to score their sense of breathlessness and
muscle fatigue throughout the exercise and at peak exer-
cise using Borg scale [26]. Oxygen saturation (SpO2), by
pulse oximetry, electrocardiographic monitoring of heart
rate (HR), oxygen uptake (V’O2), carbon dioxide pro-
duction (V’CO2) and minute ventilation (V’E) were col-
lected. Exercise parameters were compared with the
predicted normal values of Jones et al. [27]. Ventilation
was compared with the maximal ventilatory capacity
(MVC), which was estimated by multiplying the mea-
sured FEV1 by 40 [28]. The LT was detected individually
using the V-slope method [7].
Total body activity measurement
PA was assessed for five consecutive days. We used the
SenseWear Pro3 Armband (BodyMedia Inc., Pittsburgh,
PA, USA) which has been validated in CF [29,30]. The
sensor contains a biaxial accelerometer (longitudinal and
transverse), a galvanic skin response sensor, a heat flux sen-
sor, a skin temperature sensor and a near-body ambient
temperature sensor from which the data were stored mi-
nute by minute. Using specific software these variables, as
well as body weight, height, handedness and smoking sta-
tus (smoker or non-smoker), were used to estimate the in-
tensity of PA, expressed in metabolic equivalents (METS),
total energy expenditure, active energy expenditure (i.e. the
number of calories per day due to a physical activity), phy-
sical activity duration, time lying down and sleep duration.
All subjects positioned the armband on the upper right
arm (on the triceps point), as recommended by themanufacturer, and they wore it day and night only remov-
ing it for bathing or showering. Patients and healthy con-
trols were asked to continue their normal daily activities
and patients were asked to continue any respiratory-
related medications. The outputs obtained from the arm-
band was the time spent in PA at different intensities and
the definitions for activity levels based on METS were
those used by Troosters et al. [15]. The time (min) spent
with an energy expenditure of 3–4.8 METS was considered
“mild” activity (e.g., walking at normal walking speed, car-
rying out light household work), time spent at 4.8-7.2
METS was considered “moderate” activity (e.g., brisk
walking or cycling) and activities with an energy expen-
diture of >7.2 METS were considered “vigorous” (e.g.,
running or activity with training effects when applied for a
sufficient length of time and at an appropriate training fre-
quency) [31]. Finally, the number of steps was measured.
Statistical analysis
Categorical data were presented as number and percen-
tage and comparisons done using the chi-square (χ2) test
or Fisher’s exact test. Numeric data were presented as
mean ± standard deviation (SD), for normally distributed
data and comparisons done using the two sample inde-
pendent t-test, while non-normal numeric data were
presented as median (interquartile range, IQR) and com-
parisons done using the Mann–Whitney U test.
Assessment of significant changes in physiological and
ventilator parameters (i.e. SpO2) from rest to peak of ex-
ercise during CPET was performed, within each group
of patients, by the use of the paired samples t-test and
the Wilcoxon signed rank test for variables assuming
normal and non-normal distribution, respectively.
Since activity monitoring data were not normally distri-
buted the comparison of physical activity data was per-
formed using a Mann–Whitney test in order to investigate
the differences between CF patients and healthy controls.
These data are reported as median (IQR).
Spearman correlations were utilized to investigate asso-
ciations such as the relationship between oxygen uptake (at
lactic threshold and peak exercise) and PA in the CF group.
To investigate whether exercise capacity was different
between CF patients and healthy controls, after correcting
for potential confounding covariates like age, BMI, FEV1
and gender, the latest square means were computed for
the dependent variables using a generalized linear models
procedure. These analyses were done for variables that
were normally distributed. A pragmatic decision was
taken to set the significance level at p ≤ 0.01 to correct for
multiple comparisons.
Results
The study population comprised 30 patients with CF
and 15 controls. Baseline characteristics, pulmonary
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are shown in Table 1. There were no significant diffe-
rences in terms of age, sex and body mass index (BMI)
between the groups. Of the CF group, 83.3% (n = 25)
had pancreatic insufficiency and 43.3% (n = 13) were
homozygous for the mutation F508del (all remaining pa-
tients were compound heterozygous F508del with the
exception of one patient who had an unidentified second
mutation). One patient had CF-related diabetes and all
patients had chronic pulmonary infection (Pseudomonas
aeruginosa, n = 26; Staphylococcus aureus, n = 3, Bur-
kholderia cenocepacia complex, n = 1). Smoking history
was negative for all patients and controls.
Daily physical activities
Habitual daily PA of the CF patients and of the age and
sex-matched controls included in the study group is
shown in Table 1 and in Additional file 1: Table E1 of
the online supplement. The number of steps, PA at mild,
moderate and vigorous intensity was not different in CF
patients compared with healthy control subjects.Table 1 Anthropometric characteristics, pulmonary
function and daily physical activities in patients with
cystic fibrosis (CF) and in healthy control subjects
Characteristics CF (n = 30) Control (n = 15) p-value
Male/Female 20/10 10/5 1
Age, yr 33 ± 9 29 ± 5 0.19
BMI, Kg/m2 22.5 ± 2.7 23.6 ± 3.1 0.23
Pulmonary function
FEV1,L 2.65 ± 0.8 4.51 ± 0.96 <0.0001
FEV1, % predicted 71 ± 19 109 ± 11 <0.0001
FEV1/FVC, % 68 ± 11 83 ± 3 <0.0001
FVC, L 3.84 ± 1.05 5.35 ± 1.09 <0.0001
FVC, % predicted 86.4 ± 16.7 111 ± 9 <0.0001
TLC, % predicted 96.6 ± 16.3 104 ± 9 0.09
DLCO, % predicted 80.2 ± 14 94 ± 11 0.002
MVC, L/min 105.9 ± 32 180.2 ± 38.5 <0.0001
Daily physical activity
Steps, number/day 9160.5 ± 3825.6 10591 ± 4024.6 0.25
Mild intensity activities,
min/day
159 (100–246) 147 (77–205) 0.22
Moderate intensity activities,
min/day
13 (9–29) 11 (7–16) 0.34
Vigorous intensity activities,
min/day
1 (0–3) 1 (0–5) 0.94
Moderate + Vigorous
intensity activities, min/day
16 (9–29) 12 (8–27) 0.43
Definition of abbreviations: CF = Cystic Fibrosis; BMI = body mass index;
FEV1 = forced expiratory volume in one second; % pred = % predicted;
FVC = forced vital capacity; MVC = maximal ventilator capacity estimated as
40 × FEV1; TLC = total lung capacity. Data are presented as mean ± SD or
median (interquartile range), unless otherwise stated.Relationship between daily physical activities and CPET
PA of moderate (4.8-7.2 METS) intensity was related to
V’O2 uptake at LT, expressed as absolute (R = 0.44,
p = 0.01) and relative to body weight (R = 0.49, p = 0.005).
Physical activities above the threshold of moderate
(4.8-7.2 METS) and vigorous (>7.2 METS) intensity
were also related to V’O2 uptake at LT, expressed as
absolute (r = 0.45, p = 0.01) and relative to body weight
(r = 0.46, p = 0.009; Figure 1a). There was a relationship
between PA and work rate at LT (moderate PA: R = 0.5,
p = 0.004; moderate and vigorous PA: R = 0.52, p = 0.002,
Figure 1b).
Habitual PA at moderate intensity was positively related
to V’O2,peak, expressed relative to body weight, (R = 0.49,
p = 0.005). Time spent in moderate and vigorous daily
activities was correlated to V’O2,peak both expressed as
absolute and relative to body weight (R = 0.41, p = 0.02;
R = 0.51, p = 0.003, Figure 1a) and to Wattmax (R = 0.35,
p = 0.05; Figure 1b).
Lung function was not related to the PA outcomes or to
the CPET parameters at LT. There was a relationship bet-
ween FEV1 expressed as absolute value and both V’O2,peak
and Wattmax (R = 0.45, p = 0.01; R = 0.62, p = 0.0002,
respectively).
Physiological responses to CPET
Measurements at the LT and at peak exercise are shown
in Table 2. CF patients and controls reached their LT at a
similar V’O2 and work rate. Patients with CF stopped ex-
ercise at a lower peak V’O2, work rate and HR than
healthy controls. Significant differences at peak exercise
remained between the healthy control group and CF pa-
tients after correcting for the covariates age, gender, BMI
and FEV1. Both the CF patients and the healthy control
group stopped exercise primarily because of leg discom-
fort. At the end of exercise, dyspnea and leg discomfort in-
tensity were rated 1.4 and 1.5 Borg units higher in the
control group compared with CF patients, respectively.
The relationships of V’O2 versus (vs) work rate as well
O2 pulse vs work rate were not different between the
two groups throughout the exercise (Figure 2a-c). V’E in
the CF group was higher at submaximal exercise inten-
sity compared with the healthy group, except at 30 W
and 50 W: mean differences in V’E ranged from approxi-
mately 4 L/minute at 70 W (p = 0.0003) to 5 L/min at
90 W (p = 0.0003; Figure 2d). The mean peak V’E in CF
was less than the predicted MVV with breathing reserve
of 31 ± 20%, suggesting that a ventilatory limit was not
generally reached. There was no difference in V’E ex-
pressed as absolute at the LT between the two groups.
Discussion
The main finding of this study is that daily PA, particu-
larly of moderate intensity or greater, correlated with
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Figure 1 Relationship between the time spent in physical activities (PA) above moderate (4.8-7.2 METS) and vigorous (>7.2 METS) intensity and
a) oxygen uptake (V’O2) at lactic threshold (LT) r = 0.46, p = 0.009 and at peak r = 0.51, p = 0.003, b) watt at lactic threshold (LT) r = 0.52, p = 0.002 and
peak r = 0.35, p = 0.05 in patients with cystic fibrosis. □ Values at lactic threshold, ■ values at peak of exercise.
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and work rate at LT. Additionally, clinically stable adults
with CF and healthy controls have similar daily PA levels
and they presented with a V’O2 response to CPET and a
V’O2 at LT comparable to healthy controls.
To our knowledge, this study is the first to investigate
the relationship between submaximal exercise data and
PA in clinically stable adults with CF and mild to mo-
derate lung disease. The LT is an excellent submaximal
index of aerobic performance, information that is di-
rectly relevant to a patient’s ability to carry out the tasks
of daily living and allows determination of the optimum
training intensity in a given individual [7]. We demon-
strate that in this clinically stable CF population submaxi-
mal CPET indices of aerobic performance are objectively
associated with measurements of daily PA. When the rela-
tionship between habitual PA and CPET responses was
explored in the CF group, there appeared to be significantassociations. It was found that PA at moderate and vigo-
rous intensity was closely related to LT parameters,
namely V’O2 and work rate. Similarly, moderate and vigo-
rous PA was related to VO2,peak and to maximal workloads
suggesting that daily PA might play an important role in
maintaining aerobic fitness in clinically stable adults with
CF. In addition, we postulate that early changes in daily ha-
bitual PA may indicate a decline in exercise capacity and
therefore may be a sensitive marker of early change in a
patient’s disease status. The use of accelerometers has re-
ceived increasing interest in chronic respiratory diseases
[32] and several studies have validated its use in CF
[29,30]. So, the possibility of monitoring the CF state of
aerobic fitness by measuring habitual physical activity with
a portable accelerometer offers obvious advantages.
There are only few studies in which PA levels were
objectively assessed and compared with exercise capacity
in an adult CF population. The largest study of Hebestreit
Table 2 Measurements at the lactic threshold and at peak symptom-limited incremental cycle exercise
LT Peak exercise
Variable CF (n = 30) Control (n = 15) p-value CF (n = 30) Control (n = 15) p-value
Dyspnea, Borg scale 1 ± 1 1.1 ± 1.3 0.8 4.5 ± 2.3 5.9 ± 2.1 0.02
Leg discomfort, Borg scale 1.2 ± 1.07 1.3 ± 1.3 0.8 6 ± 1.9 7.5 ± 1.3 0.01
Work rate, W 80 ± 35 88 ± 25 0.4 168.6 ± 35.6 214 ± 53 0.001
% predicted maximum 41.3 ± 14.9 40 ± 7 0.7 89.03 ± 18.6 97.2 ± 15 0.1
V’O2, ml/min 1186.2 ± 327 1373 ± 306 0.07 1910.8 ± 468.6 2663.2 ± 774 0.001
% predicted maximum 47 ± 9 48 ± 7 0.66 76 ± 13 93 ± 16 0.0006
V’O2 ,ml/min/kg 17.9 ± 4 18.7 ± 2.3 0.48 28.7 ± 5.02 35.9 ± 6 0.0001
HR, beats∙min−1 118 ± 16 119 ± 15 0.84 154 ± 12 176 ± 10.5 <0.0001
% predicted maximum 63.5 ± 9 63 ± 8 0.83 83 ± 8 92 ± 3 <0.0001
O2 pulse, ml O2/beat 10.1 ± 2.5 11.6 ± 2.8 0.06 12.3 ± 2.9 15.1 ± 4.6 0.01
SpO2, % 96 ± 1.8 97.6 ± 1 0.04 94 ± 2.9 97.6 ± 0.8 <0.0001
V’E, l/min 33.3 ± 10.7 31.6 ± 5.5 0.57 69.3 ± 20.9 102.6 ± 30.9 0.0001
V’E/MVC, % 21.9 ± 5.1 19.5 ± 3.1 0.11 45.6 ± 10.5 62.3 ± 13.9 <0.0001
Definition of abbreviations: CF = Cystic Fibrosis; HR = heart rate; MVC = maximal ventilatory capacity estimated as 40 × FEV1; W = work rate; V’O2 = oxygen uptake;
V’E = maximal minute ventilation. Data are presented as mean ± SD. p values are CF versus control within the given stage of exercise.
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high aerobic capacity, but the results were obtained
recruiting a CF group aged from 12 to 40 years with a
mean age of 20 years [33]. Troosters et al. confirmed the
relationship between PA and VO2,peak in 20 CF patients
with a mean age of 25 years [15]. In keeping with that, we
confirm in our study the possible role of PA above moder-
ate intensity in the maintenance of better exercise fitness
in an older CF population. This is important since it is
generally acknowledged that PA at moderate intensity has
an important long-term protective effect on health [34]
and, as recently shown in CF, prevents muscle strength
deterioration after a hospital admission [35].
In this study, the adults with CF were able to accom-
plish their activities of daily living as much as healthy
controls with no differences in terms of PA intensity
levels between the two groups. We speculate that these
results might follow our clinical practice in terms of pa-
tient education to enhance PA levels by explaining all
the benefits associated with an active lifestyle. Using the
same motion sensor for PA monitoring and the same
METS levels, our findings were comparable to those of
Ward et al. [36] who investigated 24 adults with CF after
one month post-discharge, for the mean time spent
doing mild and vigorous PA (mild: 159 minutes in our
study vs. 163 min in Ward’s study; vigorous: 1 min vs. 3
min in Ward’s study) despite moderate PA being lower
in our study (13 vs. 43 min). Moreover, our findings are
comparable to those of Troosters et al. [15] for the num-
ber of steps (9160 vs. 9398), times spent in mild and mo-
derate PA (13 minutes in our study vs. 14.8 reported by
Troosters et al.). Vigorous PA was greater in Troosters’sstudy (1 min vs. 4.2). In this latter study the CF population
demonstrated step number and PA at mild and vigorous
intensity that was not significantly different to healthy
subjects, whereas only activities at moderate intensity
were reduced in patients with CF [15]. Conversely in our
study, we found no differences between CF and controls
in any of the PA variables measured. These results could
be explained by different PA levels of the healthy control
group, especially because our population seems to be
more sedentary than Troosters’s control group. In fact,
despite similar mild PA and number of steps (10591 in
our study vs. 10281 in Troosters’s study), PA at moderate
and vigorous intensity were lower (moderate PA 11 min
in our study vs. 34 min and vigorous PA 1 min in our
study vs. 9 min in Troosters’s study). It is possible that dif-
ferences in PA results may reflect cultural differences,
subjects’ motivation to participate in the study, a small
sample size or a sampling error. However, with the use of
a subjective method (a questionnaire) in a large CF popu-
lation, new insights into the adult CF patients’ PA habits
have been highlighted, showing similarities in moderate
and vigorous habitual PA to control groups [17]. Larger
studies may be needed to objectively confirm if adults with
CF can achieve PA levels similar to the general population.
Our study demonstrated that, despite reduced exercise
tolerance, CF patients produced V’O2 responses compar-
able to healthy controls and reached their LT at a work
rate and O2 uptake similar to that of healthy controls.
This is important if we consider that the V’O2 at which
lactate starts to increase closely reflects the fitness of an
individual and can increase with a training program [18].
The novelty of the present study was that we observed
Figure 2 (See legend on next page.)
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Figure 2 Measurements of incremental cycle exercise. a, b. Oxygen consumption (V’O2). c. O2 pulse (V’O2/HR). d. Ventilation (V’E) are
shown in response to symptom-limited incremental cycle exercise in patients with cystic fibrosis (CF) and in healthy control subjects.
Graphs represent mean ± SE values at rest; at 30, 50, 70, and 90 W during exercise; and at peak exercise. *p ≤ 0.01, CF versus control
at a standardized work rate in watts.
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were not engaged in specific home-based exercise trai-
ning. They were generally active as part of their daily
lifestyle, as evidenced by the similar levels of daily PA bet-
ween CF and healthy controls. The benefits of an exercise
program in CF have been largely established by Cerny
et al. [37] and Gruber et al. [18]. The results were ob-
tained during hospitalization for pulmonary exacerbations
or during an in-patient rehabilitation course. In both stu-
dies, CF patients were under supervision and received
several medical interventions (i.e., i.v. antibiotics, nutri-
tional supplement, airway clearance therapy, psychological
counseling), therefore making it difficult to ascertain
which of the above-mentioned factors were responsible
for the greatest effect of the observed changes. Moreover,
in a previous study, well-nourished female athletes with
CF and normal pulmonary function tests reached the LT
at a level of exercise intensity equivalent to that of healthy
subjects, suggesting similar muscle conditioning [38]. In
this sense, the similarity observed in our study between
CF and healthy subjects for exercise parameters measured
at LT and their correlation with PA in CF population,
made us assume that habitual PA may positively affect the
submaximal exercise parameters in adult CF.
Finally, our measurements at peak exercise revealed
that CF patients’ peak symptom-limited V’O2 was re-
duced by 24% of the predicted normal value and that
there were no differences between the CF and the
healthy group in the V’O2/work rate slopes which were
within the normal range. The present study focused on
the role of daily physical activity; other factors which
may contribute to the reduced exercise tolerance in CF
patients were not investigated in detail.
We recognize limitations of the present study. Firstly,
this study involved a relatively small number of partici-
pants, the majority of which were male, so this limits its
generalizability. Secondly, our healthy controls are disease-
free but possibly sedentary, even if they were recruited
from staff and colleagues of our hospital and they were
physiotherapists, students and doctors. Unfortunately, it
was technically difficult to recruit a different control group
at the time we conducted the study. Further research in-
cluding a bigger population both for CF patients and for
healthy control is needed to highlight potential differences
in habitual PA and to better characterize their lifestyle.
Finally, CPET variables have been reported to predict sur-
vival in CF [1,2] but whether this holds true or not for PAis unknown. Further studies are needed to evaluate the in-
fluence of regular PA on this and other important clinical
outcomes in CF.
Conclusions
Daily PA positively correlated with aerobic capacity in
adults with CF and mild to moderate lung function im-
pairment and was similar to healthy controls. We have
also shown that V’O2 profile and the V’O2 at LT were
comparable between healthy controls and patients with
CF. These data suggest daily PA could be considered a
valuable tool in the assessment of aerobic fitness in adult
CF population. Measuring PA is straightforward and
could easily be integrated into interventional exercise
trials. Further studies are required to determine if PA
measurements are sensitive enough to detect early pa-
thophysiological changes in CF exercise capacity, in
order to consider them as a simple and practical method
for monitoring the disease status.
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